Navigation Links
LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase
Date:4/30/2008

and the RIF ($0.2 million).

Business Outlook

The Company reaffirmed its 2008 guidance of $47 - $48 million in net sales and a $4.3 million operating loss. The Company's guidance does not include the impact of future acquisitions or significant distributor terminations.

Conference Call Reminder

Management will conduct a conference call at 5:00 p.m. EDT today to review the Company's financial results and discuss its business outlook for 2008. The conference call will be broadcast live over the internet. Individuals who are interested in listening to the webcast should log on to the Company's website at http://www.lemaitre.com/investor. The conference call may also be accessed by dialing 866-831-6247 (1-617-213-8856 for international callers) using passcode: 22576785. For interested individuals unable to join the live conference call, a replay will be available on the Company's website.

About LeMaitre Vascular

LeMaitre Vascular is a provider of devices for the treatment of peripheral vascular disease. We develop, manufacture and market disposable and implantable vascular devices to address the needs of vascular surgeons. The Company's devices are used to treat peripheral vascular disease, a condition that we estimate affects more than 20 million people worldwide.

Well-known to vascular surgeons, the Company's diversified product portfolio consists of brand name devices that are used in arteries and veins outside of the heart including the Expandable LeMaitre Valvulotome and the Pruitt-Inahara Carotid Shunt. Recent acquisitions include Vascular Architects, a manufacturer of remote endarterectomy devices, and Biomateriali, a manufacturer of vascular grafts.

LeMaitre and the LeMaitre Vascular logo are registered trademarks, and Biomateriali and TT are trademarks, of LeMaitre Vascular, Inc. This press release contains trademarks and trade names of the Compa
'/>"/>

SOURCE LeMaitre Vascular, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. LeMaitre Vascular to Participate in 28th Annual Cowen and Company Health Care Conference
2. LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer
3. LeMaitre Vascular Appoints Russell D. Hays to Its Board of Directors
4. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
5. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
6. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
7. Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials
8. ES Vascular Receives CE Mark for its First Aortic Stapler for End-to-End Anastomosis Between Synthetic Grafts and Aorta During Open Repair of Aortic Aneurysmal and Occlusive Disease
9. BRISTOL-MYERS SQUIBB SELECTS ISIS DRUG TARGETING PCSK9 AS DEVELOPMENT CANDIDATE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE
10. Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over
11. Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Nevada City, CA (PRWEB) August 28, 2014 ... and sanitation products for the food processing industry, is ... conducting a side-by side comparison of the E2 soap ... Q E2 Sanitizing Foam Soap . Hand hygiene ... pathogens in the food processing environment. Six key criteria ...
(Date:8/28/2014)... WEST LAFAYETTE, Ind. A new research ... "nanomechanical" properties of tiny structures undergoing stress ... insights to improve designs for microelectronics and ... spectroscopy, reveals information about how heating and ... their mechanical properties. Researchers have discussed the ...
(Date:8/28/2014)... The ability for organizations to attract ... allow individuals to perform at the highest of levels, ... looking to compete in this post–recession era. The ... as the sector increasingly focuses on the importance of ... have real results on the organization's development and the ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Sterlitech is ... polymeric membranes to its stable of products . ... molecular weight cut-offs and include membrane filters with surface ... increase in customer demand for our membrane process testing ... variety of flat sheet membranes,” explains Sterlitech President Mark ...
Breaking Biology Technology:Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters 2
... the First Therapies to Address the Underlying Cause ... Paradigm -, SOUTH PLAINFIELD, N.J., Aug. 20 ... Lancet show that the investigational oral drug,PTC124 demonstrates ... that treatment with PTC124 results in statistically significant,improvements ...
... Aug. 20 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq:,ONTY) (TSX: ... from The Nasdaq,Stock Market on August 14, 2008 ... for continued listing on The NASDAQ Global Market,because ... specifies, among,other things, that (i) the market value ...
... Aug. 20 Crystal Research Associates, LLC,announced ... Informational Overview(R),(EIO(R)) on Generex Biotechnology Corporation (Nasdaq: ... be found at http://www.crystalra.com ., ... is a,specialty pharmaceutical company that aims to ...
Cached Biology Technology:PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 2PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 3PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 4PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 5Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market 2Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market 3Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation 3
(Date:8/28/2014)... A Mayo Clinic researcher and his collaborators have ... and enhance the process of re-engineering cells for biomedical ... network biology methods to aid stem cell engineering. Details ... are described in two back-to-back papers in the journal ... broad range of uses for all types of cell-based ...
(Date:8/28/2014)... Access to Research Careers) Program has announced the ... America,s 27th Annual Mouse Molecular Genetics Conference from ... Grove, California. These awards are meant to ... scientists from underrepresented groups into the mainstream of ... participation of young scientists at the Genetics Society ...
(Date:8/28/2014)... -- Scientists have identified the developmental on-off switch for ... produce more than two-thirds of the world,s naturally derived ... to see whether it is possible to manipulate this ... , The study, appearing August 28 in Cell ... molecule called cyclic-di-GMP and a larger protein called BldD ...
Breaking Biology News(10 mins):New tool aids stem cell engineering for medical research 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... incite the body to attack its own nerve tissue ... viral and nerve proteins. The dual-receptor observation suggests a ... triggered in susceptible young adults afflicted with multiple sclerosis ... scientists Qingyong "John" Ji, Antoine Perchellet, and Joan M. ...
... LAFAYETTE, Ind. - Isolating a gene that allows a type ... researchers hope to use the finding to create plants that ... metal. The fern Pteris vittata can tolerate 100 to ... professor of botany and plant pathology, and David Salt, a ...
... at Chicago have discovered that an unexpected cellular response ... the formation of excess scar tissue in wound healing. ... Nature Cell Biology . When an organism ... wound site that rapidly produce extracellular matrix proteins such ...
Cached Biology News:Virus infection may trigger unusual immune cells to attack nerves in multiple sclerosis 2Virus infection may trigger unusual immune cells to attack nerves in multiple sclerosis 3Virus infection may trigger unusual immune cells to attack nerves in multiple sclerosis 4Fern's evolution gives arsenic tolerance that may clean toxic land 2Researchers discover mechanism that limits scar formation 2
... BIP-NC H-IPMIK-OH Lyophilized ... FROM LIGHT. HYGROSCOPIC. PACKAGED UNDER INERT GAS. ... Peptide, V5 (Cat. No. 196810) that serves ... Bax-mediated apoptosis (~200 μM). Purity: ≥97% ...
BD Falcon microtest assay plate. 1536 well 12l, black, flat-bottom PS. Polystyrene, nonsterile, no lid. (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
... flexible, fully automated microplate strip washer for 96- ... automated microplate strip washing capability, the Columbus combines ... operation. , Features ... 8, 12 or 16 channels, crosswise aspiration, overflow ...
... Model 1575 immunowash microplate washer 100-240 V, ... have flat-, U-, or V-bottom wells. The ... and vertical needle positions to an accuracy ... aspiration, and overflow washing. It can store ...
Biology Products: